Tissue-Specific Targeting Strategies with PROTAC Technology

This chapter provides an in-depth exploration of PROTAC (Proteolysis Targeting Chimeras) technology, a novel approach to drug discovery that harnesses the ubiquitin-proteasome system to selectively degrade disease-causing proteins. The mechanisms of action of PROTACs, including the recruitment of E3 ubiquitin ligases to target proteins, are elucidated, emphasizing the importance of target tissue detectivity in achieving therapeutic specificity. Factors influencing target tissue detectivity, such as ligand binding specificity, cellular localization of target proteins, stability, pharmacokinetics, and cell signaling pathways, are discussed in detail. Methods for assessing target tissue detectivity, including in vitro assays and in vivo models, provide valuable tools for evaluating PROTAC efficacy and selectivity. Case studies highlight successful examples of PROTAC-mediated protein degradation in various disease settings, underscoring the potential of this technology in drug discovery and therapeutics. Despite challenges and limitations, including the need for optimization of PROTAC design, pharmacokinetics, and drug delivery, PROTACs offer promising implications for overcoming drug resistance, expanding the druggable target space, and improving patient outcomes.